English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Context The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) collaborated to develop an evidence-based guideline for optimal human epidermal growth factor receptor 2 (HER2; also sometimes referred to as c-neu or c-erbB-2) testing performance in invasive breast cancer (J Clin Oncol 25:118-145, 2007). The ASCO/CAP Expert Panel, composed of a range of experts in clinical medicine, pathology, and health services research, conducted a systematic review of the literature to formulate recommendations for improving the accuracy of HER2 testing and its utility as a predictive marker.

journal of oncology practice

Guideline Summary: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor HER2 Testing in Breast Cancer